Upcoming catalysts in the fourth quarter of 2024 include US approval decisions for Upstaza for the treatment of aromatic L-amino acid decarboxylase (AADC) deficiency, zanidatamab for the treatment of biliary tract cancer, and crinecerfont for the treatment of congenital adrenal hyperplasia.

The author declares no competing interests.